. Overall, 535 of 2012 measles cases (26.6%) were imported; 1477 (73.4%) were acquired in the United States.
Measles incidence was 0.39 (95% CI, 0.37-0.41) per million population. Incidence per million population was highest in infants aged 6 to 11 months (5.44 [95% CI, .34]) and toddlers aged 12 to 15 months (5.38 [95% CI, .51]). Measles rates declined with age beginning at 16 months.
The annual number of measles cases varied between 24 and 658, and incidence per million population varied between 0.08 (95% CI, 0.05-0.12) and 2.06 (95% CI, 1.91-2.22) ( Table 2 ). Higher incidence per million population was noted over time, from 0.28 (95% CI, 0.22-0.35) in 2001 to 0.56 (95% CI, 0.48-0.65) in 2015 (P < .001). The proportion of cases that were imported and vaccinated also varied by year but decreasing trends were observed. Imported cases ranged between 9.5% and 73.0% of all cases and decreased from 46.6% (95% CI, 37.2%-56.1%) in 2001 to 14.7% (95% CI, 10.0%-20.5%) in 2015 (P < .001). Vaccinated patients ranged between 5.5% and 29.6% of US cases and decreased from 29.6% (95% CI, 20.0%-40.8%) in 2001 to 20.2% (95% CI, 14.6%-26.9%) in 2015 (P < .001).
Discussion | The annual incidence of measles in the United States remained extremely low (<1 case/million population), in line with the absence of indigenous transmission 5 and compared with incidence worldwide (40 cases/million population). 6 Relative increases in measles rates were observed over the period. Ten of 13 outbreaks with 20 or more cases occurred after 2010. 1,2 The concurrent increase in incidence and declines in the proportion of imported and vaccinated cases (signifying relative increases in US-acquired and unvaccinated cases) may suggest increased susceptibility and transmission after introductions in certain subpopulations. Given modest changes and year-to-year variability, cautious interpretation is warranted. The declining incidence with age, the high proportion of unvaccinated cases, and the decline in the proportion of vaccinated cases despite rate increases suggest that failure to vaccinate, rather than failure of vaccine performance, may be the main driver of measles transmission, emphasizing the importance of maintaining high vaccine coverage.
Limitations include lack of verifiable immunization on 48% of adults and the possibility of reporting changes, although sustained surveillance adequacy has been documented.
1 Concerns about susceptibility pockets underscore the need for continued surveillance and rapid containment strategies. 
COMMENT & RESPONSE

Ferric Carboxymaltose to Treat Isovolemic Anemia
To the Editor In a randomized clinical trial, Dr Kim and colleagues 1 found that among adults with isovolemic anemia following radical gastrectomy, ferric carboxymaltose compared with placebo resulted in improved hemoglobin response at 12 weeks. We are concerned about the uncertain internal validity and selective outcome reporting in the article. Patients 20 years or older with moderate anemia (hemoglobin level, ≥7-<10 g/dL) at 5 to 7 days after gastrectomy for gastric cancer were eligible for this study. However, patients were not excluded if they had clinical or laboratory evidence of other causes of anemia, such as poor nutrition (vitamin B 12 and folate), abnormal hormone levels, bone marrow disease, inherited conditions, and some chronic diseases (HIV/AIDS, rheumatoid arthritis, Crohn disease, or other chronic inflammatory diseases).
2 Those types of anemia may not respond to the use of iron therapy. If the distribution of other types of anemia were unbalanced between the groups, a possible bias might exist. The investigators reported outcomes that were different than those initially registered in ClinicalTrials.gov. According to the registration, there were 6 original secondary outcomes, but 1 of them, average time to response, was not reported in the article. Selective reporting of outcomes can distort the interpretation of a study. Limited data on the reversal of certain types of anemia (such as sickle cell and HIV/AIDS-induced anemias) with intravenous iron demonstrate the importance of excluding such patient populations. However, 3 points ameliorate this concern. First, the exclusion criteria did eliminate patients with anemia induced by chronic, inherited, or severe conditions. Among other specifications, patients with concurrent medical conditions that jeopardized health, active infection or inflammation, or an American Society of Anesthesiologist (ASA) score greater than 3 were excluded from the study. Second, the prevalence of other anemia types that may have been overlooked by the exclusion criteria is small and should have been distributed equally in both groups. A study that evaluated the incidence and etiology of postgastrectomy anemia in 161 patients with gastric cancer found that noniron-related causes of anemia-such as megaloblastic and vitamin B 12 deficiency anemias-were rare. 1 Third, most importantly, the ultimate purpose of this study was to find an effective method of anemia reversal that could potentially replace the use of blood transfusions. Emerging evidence strongly supports restrictive transfusion practices, 2 and therefore clinicians need other therapeutic options to replace this once-popular method of anemia reversal. Administration of intravenous ferric carboxymaltose resulted in robust recovery rates from moderate anemia (92.2% [200 patients] for the ferric carboxymaltose group vs 54.0% [115 patients] for the placebo group; P = .001), despite the potential inclusion of patients with causes of anemia other than blood loss. Subgroup analysis also showed favorable hemoglobin response regardless of iron deficiency. These results suggest that the use of intravenous ferric carboxymaltose to treat various types of anemia other than the one described in this study deserves further research.
Regarding the discrepancy between the registration of the study on ClinicalTrials.gov and the reported outcomes, the "average time to response" was removed at the start of the trial (and therefore not reported) because we realized that continuous measurements of laboratory values were logistically infeasible. Although this protocol amendment was not reflected in the registry, this change was reviewed and approved by the institutional review board, and dated documentation of this modification was made available in the Supplement.
